Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry
The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft
Cancer Research UK has provided £5.9 million ($7.7 million) in funding to a project that will explore the use of artificial intelligence in trials of radiotherapy treatments as well as virt
